A recent international study published in the journal Nature Medicine has revealed that India is projected to face the world's second-highest economic burden due to diabetes, amounting to an estimated USD 11.4 trillion (International Dollars) between 2020 and 2050. This comprehensive analysis, conducted by researchers from the International Institute for Applied Systems Analysis (IIASA) and the Vienna University of Economics and Business in Austria, examined the economic impact of diabetes across 204 countries. The United States ranks highest with an economic burden of USD 16.5 trillion, while China follows India in third place with USD 11 trillion. The study highlights that the global economic costs of diabetes, excluding informal care provided by family members, are approximately USD 10 trillion, representing about 0.2% of the world's annual GDP. However, when informal care is factored in, the total global cost escalates dramatically to an estimated USD 152 trillion, or 1.7% of the world's yearly GDP. Informal caregiving accounts for nearly 90% of this total burden, largely because diabetes prevalence significantly outweighs mortality rates. For nations like India and China, the substantial economic costs are primarily attributed to their vast diabetic populations. In contrast, the burden in higher-income countries like the United States stems mainly from high treatment expenses and the diversion of physical capital. The researchers underscore that the economic impact of diabetes surpasses that of other major diseases such as Alzheimer's and cancer. This dire projection necessitates urgent public health interventions. Experts advocate for promoting healthier lifestyles, regular physical activity, balanced diets, universal screening, early diagnosis, and timely treatment as crucial strategies to mitigate both the health and economic consequences of diabetes in India and globally.